Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis

BACKGROUND: The elevated calcium and phosphorus levels in patients undergoing hemodialysis may increase the risk of all-cause mortality. Paricalcitol, as a new vitamin D receptor activator (VDRA), seemed to be effective in reducing the calcium and phosphorus levels. OBJECTIVES: The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Liu, Ling-Yun, Jia, Ye, Wu, Mei-Yan, Sun, Yan-Yan, Ma, Fu-Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445244/
https://www.ncbi.nlm.nih.gov/pubmed/30992658
http://dx.doi.org/10.2147/DDDT.S176257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445244/
https://www.ncbi.nlm.nih.gov/pubmed/30992658
http://dx.doi.org/10.2147/DDDT.S176257

Ejemplares similares